[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"minimal-change-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:minimal-change-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,55,85,113,141,160,193,223,250,273,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":37,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100406380","neptune-match-study-100406380",false,"NCT04571658","NEPTUNE Match Study","Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)","NEPTUNE Match","Inclusion Criteria:\n\n1. Consented and eligible participants in the biopsied or non-biopsied cohorts of the NEPTUNE observational study\n2. Must be potentially eligible for the NEPTUNE Match partnering trials (e.g. if no trial is enrolling a participant under age 6, those under 6 are not eligible).\n\n   Note: NEPTUNE Match partnering trials and associated eligibility criteria are expected to be dynamic and change as trial protocols are developed, activated, and amended.\n3. Regular nephrology healthcare provided at a NEPTUNE study site.\n4. Willing and able to consent, and as appropriate assent, to participate in NEPTUNE Match\n\nExclusion Criteria:\n\nCurrently non-NEPTUNE observational study participants are not eligible to be matched to a clinical trial using these biomarker assessments.\n\nExclusion Criteria:\n\n1\\. Non-English or non-Spanish speaking","ALL","1 Year","80 Years",{"count":21,"type":22},375,"ESTIMATED","INTERVENTIONAL",[25],"NA","NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.",[28,29,30,31,32,33,34,35,36],"Nephrotic Syndrome in Children","Focal Segmental Glomerulosclerosis","Minimal Change Disease","Minimal Change Nephrotic Syndrome","Membranous Nephropathy","FSGS","MCD","MCD - Minimal Change Disease","Alport Syndrome",[38,39,40,41],"Nephrotic Syndrome","NEPTUNE","Match","Clinical Trial Match","RECRUITING","2026-06-08",{"date":45,"type":46},"2026-06-10","ACTUAL",{"date":48,"type":46},"2022-05-02",{"date":50,"type":22},"2029-12-30",{"name":52,"class":53},"University of Michigan","OTHER",16,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100439568","phase-2-study-of-sparsentan-treatment-in-pediatrics-with-proteinuric-glomerular-diseases-100439568","NCT05003986","Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases","A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases","EPPIK","Inclusion Criteria for All Subjects (All Three Populations):\n\nA subject must meet all of the following criteria to be eligible for participation in this study:\n\n* The subject or parent\u002Flegal guardian (as appropriate) is willing and able to provide signed informed consent\u002Fassent, and where required, the subject is willing to provide assent before any screening procedures per local requirements.\n* The subject has an estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m2 at screening.\n* The subject has a mean seated blood pressure between the 5th and 95th percentile for sex and height.\n\nInclusion Criteria for Population 1:\n\n* The subject is male or female ≥1 year at screening and \\\u003C18 years of age at Day 1 (Baseline).\n* The subject has a UP\u002FC ≥1.5 g\u002Fg (170 mg\u002Fmmol) at screening AND one of the following:\n* Kidney biopsy-proven FSGS or MCD histological patterns and clinical presentation consistent with primary FSGS or MCD and qualifying proteinuria at screening despite history or ongoing treatment with corticosteroids and\u002For other immunosuppressive disease-modifying agents.\n* Documentation of a genetic mutation in a podocyte protein associated with FSGS or MCD. Subjects with a documented podocytic mutation do not require kidney biopsy.\n* Kidney biopsy-proven FSGS histological pattern with medical history and clinical presentation consistent with maladaptive cause of the lesion.\n\nNote: The kidney biopsy may have been performed at any time in the past but must include light microscopy and electron microscopy characteristics and\u002For immunofluorescence findings consistent with FSGS or MCD.\n\nInclusion Criteria for Population 2:\n\n* The subject is male or female ≥2 years at screening and \\\u003C18 years of age at Day 1 (Baseline).\n* The subject has UP\u002FC ≥0.6 g\u002Fg (68 mg\u002Fmmol) at screening AND one of the following diagnoses:\n* Kidney biopsy-confirmed IgAN, IgAV, or AS\n* Diagnosis of AS by genetic testing (pathogenic X-linked Collagen, Type IV, Alpha-5 (COL4A5) mutation OR autosomal-recessive mutations in both alleles of Collagen, Type IV, Alpha-3 (COL4A3) and\u002For Collagen, Type IV, Alpha-4 (COL4A4) OR autosomal-dominant COL4A3 and\u002For COL4A4 and digenic mutations \\[ie, simultaneous mutations in 2 of the COL4A3, COL4A4, and COL4A5 genes\\])\n\nInclusion Criteria for Population 3:\n\n* The subject is male or female ≥8 years at screening and \\\u003C18 years of age at Day 1 (Baseline).\n* The subject has UP\u002FC ≥1.0 g\u002Fg (113 mg\u002Fmmol) at screening AND has kidney biopsy-confirmed IgAN\n* Subject weighs ≥40 kg\n* The subject has been on ACEI and\u002For ARB therapy for at least 12 weeks prior to screening\n\nExclusion Criteria for All Subjects (All Three Populations):\n\nA subject who meets any of the following will be excluded from this study:\n\n* The subject weighs \\\u003C7.3 kg at screening.\n* The subject has FSGS or MCD histological pattern secondary to viral infections, drug toxicities, or malignancies.\n* The subject has immunoglobulin A (IgA) glomerular deposits not in the context of primary IgAN or IgAV (ie, secondary to another condition; eg, systemic lupus erythematosus and liver cirrhosis).\n* The subject has had an acute onset or presentation of glomerular disease or a diagnostic biopsy or a relapse of glomerular disease requiring new or different class of immunosuppressive treatment (including, but not limited to, systemic corticosteroids, calcineurin inhibitors and mycophenolate mofetil, abatacept, cyclophosphamide, rituximab, ofatumumab, and ocrelizumab) within 6 months before screening.\n* Subjects taking chronic immunosuppressive medications (including systemic steroids) not on a stable dose for ≥1 month before screening.\n* The subject requires any of the prohibited concomitant medications as defined in the study protocol.\n* The subject has undergone any organ transplantation, with the exception of corneal transplants.\n* The subject has a documented history of congenital or acquired heart failure (modified Ross heart failure classification for children Class II to Class IV) and\u002For previous hospitalization for heart failure or unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, and\u002For peripheral edema.\n* The subject has hemodynamically significant cardiac valvular disease.\n* The subject has clinically significant congenital vascular disease.\n* The subject has jaundice, hepatitis, or known hepatobiliary disease, or alanine aminotransferase and\u002For aspartate aminotransferase \\>2 times the upper limit of the normal range at screening.\n* The subject has a history of malignancy within the past 2 years.\n* The subject has a screening hematocrit \\\u003C27% (0.27 L\u002FL) or a hemoglobin value \\\u003C9 g\u002FdL (90 g\u002FL).\n* The subject has a screening potassium value \\>5.5 milliequivalent (mEq)\u002FL (5.5 mmol\u002FL).\n* The subject has any abnormal clinical laboratory screening values that are considered by the Investigator to be clinically significant.\n* The subject has a history of allergic response to any angiotensin II antagonist or endothelin receptor antagonist, including sparsentan, or has a hypersensitivity to any of the excipients in the study medication.\n* The female subject is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.\n* Female subjects of childbearing potential, beginning at menarche, who do not agree to use 1 highly reliable (ie, can achieve a failure rate of \\\u003C1% per year) method of contraception from 7 days before the first dose of the study medication until 28 days after the last dose of study medication. Examples of highly reliable contraception methods include stable oral, implanted, transdermal, or injected contraceptive hormones associated with the inhibition of ovulation or an intrauterine device. One additional barrier method must also be used during vaginal sexual activity, such as a diaphragm, diaphragm with spermicide (preferred), or male partner's use of male condom or male condom with spermicide (preferred), from Day 1\u002FRandomization until 28 days after the last dose of study medication. Female subjects of childbearing potential are defined as those who are fertile after menarche, unless permanently sterile; permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. All female subjects of childbearing potential must have a negative serum pregnancy test result at screening (Visit 1) and a negative urine pregnancy test result, with positive results confirmed by serum, at every study visit from Day 1 (Visit 3) and after.\n\nNote: Before menarche, pregnancy testing and contraceptive use are not required. However, subjects and their parents\u002Flegal guardians must be advised that, immediately upon menarche, subjects will be required to begin pregnancy testing and initiate contraceptive use. This requirement cannot be waived.\n\n* The subject has participated in a study of another study medication within 28 days before screening or plans to participate in such a study during the course of this study.\n* The subject has had prior exposure to sparsentan.\n* The subject or parent\u002Flegal guardian (as appropriate), in the opinion of the Investigator, are unable to adhere to the requirements of the study including but not limited to, a history of noncompliance and\u002For any other reason that causes the Investigator to believe the subject would not be a good candidate for the study.\n* For Population 3 - the subject is unable to swallow the study medication tablets whole.","17 Years",{"count":65,"type":22},67,[67],"PHASE2","To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.",[29,30,70,71,36],"Immunoglobulin A Nephropathy","IgA Vasculitis",[73],"Alport, AS, FSGS, IgAN, IgAV, MCD, pediatrics, peds","2026-05-08",{"date":76,"type":46},"2026-05-12",{"date":78,"type":46},"2021-08-12",{"date":80,"type":22},"2027-04-12",{"name":82,"class":83},"Travere Therapeutics, Inc.","INDUSTRY",47,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100489246","recurrence-post-transplant-observational-study-in-focal-segmental-glomerulosclerosis-and-minimal-change-disease-100489246","NCT05650619","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)","RESOLVE","Inclusion Criteria:\n\n* Retrospective non-consented participant group had a transplant from the year 2000 and onward.\n* Diagnosis of FSGS or MCD in the native kidney (prior to transplant).\n\nExclusion Criteria:\n\n* Pathologic diagnosis other than FSGS or MCD\n* FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)",{"count":94,"type":22},300,"OBSERVATIONAL","The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes.\n\nThe purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.",[29,30,33,34],[99,100,101,102,103],"Kidney disease","Kidney transplant","Adult","Children","Recurrence","2026-04-23",{"date":106,"type":46},"2026-04-29",{"date":108,"type":46},"2022-12-08",{"date":110,"type":22},"2027-12",{"name":52,"class":53},1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":63,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100484123","a-pilot-trial-of-tavns-for-srns-in-children-kidney-vns-100484123","NCT05583942","A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)","A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Steroid Resistant Nephrotic Syndrome in Children","kidNEY-VNS","Inclusion Criteria:\n\n* Steroid Resistant Nephrotic Syndrome- defined as lack of remission after 4 weeks of therapy of prednisolone\u002Fprednisone at standard dose1\n* Age 3-17 years\n* eGFR ≥30 ml\u002Fmin\u002F1.73 m2 (by modified Schwartz formula)\n* MCD or FSGS diagnosis (per biopsy)\n* Urine protein:creatinine (UPC) greater than 1.0\n* Stable immunosuppression and ACE inhibitor\u002Fangiotensin receptor blocker treatment regimen for at least three months\n* Evidence of B cell repletion for those exposed to rituximab\n* Informed consent from the parent or guardian and assent from a minor of ≥ 7 years\n* Ability to comply with the study protocol, in the investigator's judgment\n\nExclusion Criteria:\n\n* Secondary causes of nephrotic syndrome (e.g. genetic, congenital, infectious)\n* Steroid sensitive nephrotic syndrome\n* History of genetic defects known to directly cause nephrotic syndrome (i.e., NPHS2 \\[podocin\\], NPHS1 \\[nephrin\\], PLCE1, WT1, or other known genetic cause)\n* Any known inflammatory condition\n* History of cardiac disease (arrhythmias, structural\u002Ffunctional abnormalities)\n* Implantable electronic devices (pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators)\n* Chronic rash or skin breakdown of the left ear at the cymba concha\n* Pregnancy","3 Years",{"count":123,"type":22},10,[25],"Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated noninvasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.",[28,30,29],[128,129,130],"vagus nerve stimulation","pediatric","nephrology","2026-04-14",{"date":133,"type":46},"2026-04-17",{"date":135,"type":46},"2022-09-19",{"date":137,"type":22},"2027-08-01",{"name":139,"class":53},"Northwell Health",2,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":119,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":63,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":140},"100484439","tavns-for-frns-in-children-100484439","NCT05588063","taVNS for FRNS in Children","A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children","Inclusion Criteria:\n\n* FRNS\n* Age 3-17 years\n* Glomerular filtration rate (eGFR) ≥30 ml\u002Fmin\u002F1.73 m2\n* Minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) diagnosis (clinical diagnosis or per biopsy)\n* Steroid sensitive nephrotic syndrome (prior history of remission within 4 weeks of steroid therapy)\n* In remission at time of enrollment (remission defined as UPC \\\u003C0.2 or negative dipstick for 3 consecutive days)\n* Informed consent from the parent or guardian and assent from a minor of ≥ 7. years\n\nExclusion Criteria:\n\n* Secondary forms of nephrotic syndrome\n* SRNS\n* Steroid dependent nephrotic syndrome (relapse within 14 days of stopping steroids or relapse while on steroids)\n* Exposure to steroids within 14 days of enrollment\n* Receiving any standing immunosuppression (previous exposure \\> 2 months allowed and\u002For B cell repletion)\n* Any known inflammatory condition (e.g. systemic lupus erythematosis)\n* History of cardiac disease (arrhythmias, structural\u002Ffunctional abnormalities)\n* Implantable electronic devices\n* Pregnancy\n* Participants\u002Fguardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures",{"count":149,"type":22},30,[25],"Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.",[28,30,29],[128,129,130],{"date":155,"type":46},"2026-04-15",{"date":157,"type":46},"2023-01-05",{"date":137,"type":22},{"name":139,"class":53},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":178,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100551903","phase-2-study-of-wal0921-in-patients-with-glomerular-kidney-diseases-100551903","NCT06466135","Study of WAL0921 in Patients With Glomerular Kidney Diseases","Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria","Inclusion Criteria:\n\n* Adults, age 18-75 years\n* Diagnosis of one of the following glomerular kidney diseases: diabetic nephropathy; primary focal segmental glomerulosclerosis; treatment resistant-minimal change disease; primary IgA nephropathy; primary membranous nephropathy\n* eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Currently pregnant or planning to become pregnant\n* History of organ transplantation\n* History of alcohol or substance use disorder\n* Acute dialysis or acute kidney injury within 6 months of Screening\n* Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and\u002For completing all study requirements","18 Years","75 Years",{"count":170,"type":22},96,[67],"This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \\[FSGS\\], treatment-resistant minimal change disease \\[TR MCD\\], primary immunoglobulin A nephropathy \\[IgAN\\], and primary membranous nephropathy \\[PMN\\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.",[174,175,30,176,177],"Diabetic Nephropathies","Primary Focal Segmental Glomerulosclerosis","Primary Immunoglobulin A Nephropathy","Primary Membranous Nephropathy",[179,33,180,181,182],"DN","TR-MCD","IgAN","PMN","2026-03-27",{"date":185,"type":46},"2026-04-02",{"date":187,"type":46},"2024-07-02",{"date":189,"type":22},"2027-06",{"name":191,"class":83},"Walden Biosciences",50,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":204,"conditions":205,"keywords":213,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":112},"100478094","interview-study-of-adult-and-child-patients-and-parents-of-children-with-swelling-due-to-nephrotic-syndrome-100478094","NCT05505500","Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.","Preparing a Clinical Outcomes Assessment Set for Nephrotic Syndrome","Prepare-NS","Criteria for the Observer Reported Outcomes (ObsRO) cohort of the study:\n\nInclusion Criteria:\n\n1. Parents\u002Fguardians must be able to read and understand English;\n2. Parents\u002Fguardians must be caring for a child (ages 2-11.999) with a medically documented diagnosis of idiopathic (primary) Nephrotic Syndrome (NS) or primary or monogenic NS associated kidney disease. Populations with Primary NS Conditions: Focal segmental glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin M (IgM) Nephropathy, Membranous Nephropathy (MN), and childhood - onset nephrotic syndrome not biopsied;\n3. The child must have a current NS-associated edema\n4. The child must have native kidney function\n5. Parents\u002Fguardians must provide informed consent.\n\nExclusion Criteria:\n\n1\\. Index case with dialysis dependence throughout the 3-month pre-enrollment period\n\nCriteria for the Patient Reported Outcomes (PRO) cohort of the study:\n\nInclusion Criteria:\n\n1. ≥8 years of age\n2. Able to read and understand English\n3. Primary (idiopathic) kidney disease that causes NS or monogenic NS associated kidney disease.\n\n   i. Populations with Primary Nephrotic Syndrome (NS) Conditions include: FSGS, MCD, IgM nephropathy, MN, and childhood - onset nephrotic syndrome not biopsied\n4. Current NS-associated edema\n5. Kidney function with most recent estimated Glomerular Filtration Rate (eGFR) \\> 25 ml\u002Fmin\u002F1.73m2\n6. Informed Consent: For patients ≥8 to \\\u003C18 years of age: a parent or legal guardian provide informed consent and the patient must provide assent. Patients ≥18 years of age must provide informed consent.\n\nExclusion Criteria:\n\n1. Native kidney disease participant with dialysis dependence during the 3-month pre-enrollment period\n2. Co-existing significant chronic or severe acute health condition that has the potential to influence how the participant feels or functions as related to fluid overload in NS","2 Years",{"count":203,"type":22},150,"Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients (child and adult) and parents of young children will be conducted. The information collected from the interviews will be used to develop a survey to use when testing new medications for Nephrotic Syndrome.\n\nPlease consider participating in a 1-hour long interview with the Prepare-NS research study to discuss children and adults experiences with swelling.",[206,207,208,32,30,31,209,38,210,211,28,212,33],"Fluid Overload","Glomerulosclerosis, Focal Segmental","Edema","IgM Nephropathy","Glomerular Disease","Nephrotic Syndrome, Minimal Change","Nephrotic Syndrome With Edema (Diagnosis)",[38,214,101,206,208,33,30,32,209],"Child","2025-12-15",{"date":217,"type":46},"2025-12-22",{"date":219,"type":46},"2022-04-18",{"date":221,"type":22},"2026-04-30",{"name":52,"class":53},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":232,"studyType":95,"phases":4,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":249},"100358661","the-forme-registry-the-german-focal-segmental-glomerulosclerosis-and-minimal-change-disease-registry-100358661","NCT03949972","The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)","FOrMe","Inclusion Criteria (cohort A):\n\n* written informed consent\n* 17 or less years of age\n* idiopathic nephrotic syndrome\n\nInclusion Criteria (cohort B):\n\n* written informed consent\n* older or equal to 18 years of age\n* biopsy-proven primary or secondary FSGS or MCD or biopsy-proven recurrence of disease in kidney transplant.\n\nExclusion Criteria (both cohorts):\n\n* Prior kidney transplant without biopsy-proven recurrence\n* A clinical diagnosis of other glomerular disease resulting in secondary MCD or FSGS as judged by the treating physicians.\n* Refusal to provide written informed consent\n* (Anticipated) incompliance with visit schedule",{"count":231,"type":22},500,"15 Years","In a monocentric, later multicentric prospective approach the FOrMe registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) aims to generate a longitudinal cohort of 150 pediatric cases of idiopathic nephrotic syndrome and 350 adult cases of biopsy-proven Minimal Change Disease (MCD) or Focal and Segmental Glomerular Sclerosis (FSGS) over 10 years. The registry will provide a repository for biomaterials such as blood samples, DNA, urine, feces, and tissue biopsies that will be accessible to collaborators to facilitate future research on pathogenesis, diagnostics, and treatment.",[207,30,235],"Idiopathic Nephrotic Syndrome",[237,238,33,239,34,38],"Focal and Segmental Glomerulosclerosis","Focal & Segmental Glomerulosclerosis","Minimal change disease","2025-09-11",{"date":242,"type":46},"2025-09-17",{"date":244,"type":46},"2018-04-01",{"date":246,"type":22},"2033-03-31",{"name":248,"class":53},"Prof. Dr. Paul Brinkkoetter",12,{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":19,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":263,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100547217","phase-3-efficacy-and-safety-of-tacrolimus-in-combination-with-ripertamab-in-the-initial-treatment-of-patients-with-mcd-100547217","NCT06405100","Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD","Efficacy and Safety of Tacrolimus in Combination With Anti-CD20 Monoclonal Antibody (Ripertamab) in the Initial Treatment of Patients With Minimal Change Disease: a Multi-center Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age 18-80 years old;\n2. Primary minimal change disease confirmed by renal biopsy (Initial therapy);\n3. 24h-UTP\\>3.5g\u002Fd or PCR\\>3500mg\u002Fg, and serum albumin\\\u003C30g\u002FL;\n4. Agree to participate in the project and sign the informed consent.\n\nExclusion Criteria:\n\n1. Secondary minimal change disease;\n2. eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2;\n3. Had history of mental disease, dysnoesia, serious cardiovascular and cerebrovascular diseases, pulmonary insufficiency, malignant tumors or other major diseases that are not suitable for clinical experiments;\n4. Active bleeding in the gastrointestinal tract;\n5. Prior treatment with corticosteroids or other immunosuppressants;\n6. HBV, HCV, HIV or other untreated infections, congenital or acquired immunodeficiency diseases;\n7. Have been vaccinated with live vaccine in the past four weeks;\n8. Serum bilirubin \\> 3.6mg\u002Fdl for at least 1 month or liver function ≥3 times the upper limit of normal value;\n9. Allergic to prednisolone, tacrolimus, or ripertamab;\n10. Reluctance to use contraception or plan pregnancy\u002Flactation within 6 months of study completion;\n11. Had history of alcohol\u002Fdrug abuse;\n12. Unable to give informed consent.",{"count":258,"type":22},81,[260],"PHASE3","To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with MCD.",[30],"NOT_YET_RECRUITING","2024-05-04",{"date":266,"type":46},"2024-05-08",{"date":268,"type":22},"2024-05",{"date":270,"type":22},"2027-04",{"name":272,"class":53},"Air Force Military Medical University, China",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":4,"enrollmentInfo":280,"targetDuration":282,"studyType":95,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":263,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100540335","circulating-factors-in-nephrotic-syndrome-100540335","NCT06315504","Circulating Factors in Nephrotic Syndrome","Circulating Factors in Nephrotic Syndrome - A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Plasma albumin \\\u003C 36 g\u002FL\n* Urine protein \\>3.5 g\u002Fday or urine protein\u002Fcreatinine-ratio (UPCR) \\> 3.5 or urine albumin\u002Fcreatinine-ratio (UACR) \\>2200 mg\u002Fg\n* Planned kidney biopsy\n* Able to give written informed consent\n\nExclusion Criteria:\n\n* Kidney transplant recipient\n* Previously undergone a kidney biopsy\n* Unable to understand written information in Danish",{"count":281,"type":22},104,"10 Years","A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.",[38,32,30,175],"2024-03-16",{"date":287,"type":46},"2024-03-19",{"date":289,"type":22},"2024-04-01",{"date":291,"type":22},"2034-04-01",{"name":293,"class":53},"Iain Bressendorff",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":302,"targetDuration":304,"studyType":95,"phases":4,"briefSummary":305,"conditions":306,"keywords":310,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100357120","korea-renal-biobank-network-system-toward-next-generation-analysis-100357120","NCT03929887","KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis","Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research","KORNERSTONE","1. Inclusion criteria\n\n   * Patient suspected of glomerular disease who received kidney biopsy in participating university medical centers\n   * Children (age\\\u003C18 years) also included\n2. Exclusion criteria - Patients who previously received a kidney transplant",{"count":303,"type":22},3000,"20 Years","Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis is uncertain.\n\nRecently, along with advances in molecular analysis and computational bioinformatics, genomic data from human renal biopsies could provide a strong foundation for the future of precision medicine in nephrology.\n\nIn response to a request for applications by the Ministry of Health and Welfare of Korea for the creation of Clinical Research Registry, multi-center N network has been established for prospective cohort with kidney biopsy samples (KORNERSTONE).\n\nThrough this Network the investigators hope to understand the fundamental biology of glomerulonephritis and aim to bank long-term observational data and corresponding biological data including genomic data from kidney tissues, and kidney pathologic data which is digitalized This database is archived to a web-based platform to access easily and further enrich for researchers.",[210,30,307,32,29,308,309],"IgA Nephropathy","Lupus Nephritis","Crescentic Glomerulonephritis",[311,312,313,314,315],"Glomerular disease","sample repository","clinical data","digital pathology repository","web-based database","2020-02-10",{"date":318,"type":46},"2020-02-12",{"date":320,"type":46},"2019-05-01",{"date":322,"type":22},"2028-12-31",{"name":324,"class":53},"Seoul National University Hospital",6]